Comparison of neutralizing antibody responses against SARS-CoV-2 in healthy volunteers who received the BNT162b2 mRNA or the AZD1222 vaccine: Should the second AZD1222 vaccine dose be given earlier?

Am J Hematol. 2021 Sep 1;96(9):E321-E324. doi: 10.1002/ajh.26248. Epub 2021 Jun 2.

Affiliations

¹ Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
² Department of Cell Biology and Biophysics, Faculty of Biology, National and Kapodistrian University of Athens, Athens, Greece.
³ Section of Pharmaceutical Technology, Department of Pharmacy, School of Health Sciences, National and Kapodistrian University of Athens, Athens, Greece.

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Neutralizing / blood
Antibodies, Neutralizing / immunology*
Antibodies, Viral / blood
Antibodies, Viral / immunology*
BNT162 Vaccine
COVID-19 / immunology*
COVID-19 / prevention & control*
COVID-19 / virology
COVID-19 Vaccines / administration & dosage
COVID-19 Vaccines / immunology*
ChAdOx1 nCoV-19
Healthy Volunteers
Humans
Immunogenicity, Vaccine
Risk Factors
SARS-CoV-2 / immunology*
Vaccination

Substances

Antibodies, Neutralizing
Antibodies, Viral
COVID-19 Vaccines
ChAdOx1 nCoV-19
BNT162 Vaccine